Sweden’s RhoVac Aims To Become An M&A Target
Late 2021 RV001 Phase IIb Data May Offer Trigger, CEO Says
RhoVac is in mid-stage trialing of a vaccine based on the RhoC protein that aids the metastatic potential of cancer cells and their ability to migrate and infiltrate other tissue. The Swedish biotech’s CEO believes the drug is a potential blockbuster.
You may also be interested in...
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.